Last reviewed · How we verify
DWJ1276
DWJ1276 is a Small molecule drug developed by Daewoong Pharmaceutical Co. LTD.. It is currently in Phase 3 development.
DWJ1276 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
DWJ1276 is a medication being studied in a clinical trial for the treatment of hypertension associated with dyslipidemia. The trial is a multi-institutional, randomized, double-blind, placebo-controlled study comparing DWJ1276 to olmesartan and rosuvastatin.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DWJ1276 |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without publicly available clinical trial data or mechanism disclosures, the precise molecular target and pharmacological action of DWJ1276 remain unknown. As a phase 3 candidate, it has progressed through early safety and efficacy testing, but detailed mechanistic information is not yet in the public domain.
Approved indications
Common side effects
Key clinical trials
- Clinical Study for Patients With Hypertension Associated With Dyslipidemia (PHASE3)
- Safety and Pharmacokinetic Comparison of Co-administration and a Combination Drug of Rosuvastatin and Olmesartan in Healthy Male Volunteers (PHASE1)
- A Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DWJ1276 CI brief — competitive landscape report
- DWJ1276 updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI
Frequently asked questions about DWJ1276
What is DWJ1276?
How does DWJ1276 work?
Who makes DWJ1276?
What development phase is DWJ1276 in?
Related
- Manufacturer: Daewoong Pharmaceutical Co. LTD. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing